psilocybin (COMP360) / Compass Pathways 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...234567891011121314»
  • ||||||||||  Desoxyn (methamphetamine) / Lundbeck, psilocybin / Compass Pathways
    Preclinical, Journal:  Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. (Pubmed Central) -  Jul 24, 2019   
    The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enforcement Administration...Effects of repeated LSD were also examined to evaluate potential changes in its own effects on ICSS or changes in effects produced by the abused psychostimulant methamphetamine or the prodepressant kappa opioid receptor (KOR) agonist U69,593...Repeated LSD treatment failed to alter either its own ICSS depressant effects or the abuse-related effects of methamphetamine; however, repeated LSD did attenuate ICSS depression by U69,593. These results extend those of previous preclinical studies to suggest weak expression of abuse-related effects by 5-HT2A agonist hallucinogens and provide supportive evidence for therapeutic effects of repeated LSD dosing to attenuate KOR-mediated depressant effects but not abuse potential of psychostimulants.
  • ||||||||||  psilocybin / Compass Pathways
    Journal:  Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. (Pubmed Central) -  Jul 17, 2019   
    This is the first time that these measures have been applied to the psychedelic state and, crucially, that they have yielded values exceeding those of normal waking consciousness. These findings suggest that the sustained occurrence of psychedelic phenomenology constitutes an elevated level of consciousness - as measured by neural signal diversity.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Enrollment open:  The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (clinicaltrials.gov) -  Jul 12, 2019   
    P2,  N=216, Recruiting, 
    These findings suggest that the sustained occurrence of psychedelic phenomenology constitutes an elevated level of consciousness - as measured by neural signal diversity. Not yet recruiting --> Recruiting
  • ||||||||||  psilocybin / Compass Pathways
    Journal:  Trends in Abuse of Biogenic Drugs in Parts of Germany 2007-2013 (Pubmed Central) -  Jun 15, 2019   
    The results underline the dominance of Angel's trumpet in the abuse of biogenic drugs and emphasize the importance of easy accessibility for the abuse of biogenic drugs. Unexpectedly, the number of nutmeg abuse cases increased during the investigated period.
  • ||||||||||  psilocybin / Compass Pathways
    Journal:  Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. (Pubmed Central) -  Jun 15, 2019   
    Recent, well-controlled - albeit small-scale - clinical trials show that serotonergic psychedelics, including psilocybin and lysergic acid diethylamide, possess great promise for treating psychiatric disorders, including treatment-resistant depression...These chiefly pertain to molecular neuropharmacology. This chapter is devoted to illuminating and discussing such questions in the context of preclinical experimental approaches for studying mechanisms of action of serotonergic psychedelics, classic and new.
  • ||||||||||  psilocybin / Compass Pathways
    Journal:  Denver votes to decriminalise psilocybin mushrooms. (Pubmed Central) -  Jun 5, 2019   
    This chapter is devoted to illuminating and discussing such questions in the context of preclinical experimental approaches for studying mechanisms of action of serotonergic psychedelics, classic and new. No abstract available
  • ||||||||||  psilocybin / Compass Pathways
    Journal:  Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. (Pubmed Central) -  May 15, 2019   
    In addition to psilocybin, a wide variety of agents with psychedelic properties have been proposed and partially tested. However, the challenges of obtaining approval to market a restricted psychotomimetic agent are formidable.
  • ||||||||||  psilocybin / Compass Pathways
    Review, Journal:  Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. (Pubmed Central) -  May 9, 2019   
    ...Recent studies have shown that serotonergic hallucinogens (i.e. ayahuasca, dimethyltryptamine, psilocybin, lysergic acid diethylamide [LSD], and mescaline) have anxiolytic and antidepressant properties, but their effects on REFE are not well understood...Serotonergic hallucinogens reduced the recognition of negative emotions by modulating amygdala activity. Despite the small sample sizes, results suggest that serotonergic hallucinogens show promising beneficial effects on deficits in REFE.